Livzon Pharmaceutical Group Overview
- Founded
-
1985
- Status
-
Public
- Employees
-
8,693
- Stock Symbol
-
000513
- Investments
-
15
- Share Price
-
$5.05
- (As of Tuesday Closing)
Livzon Pharmaceutical Group General Information
Description
Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's portfolio primarily comprises western pharmaceutical preparations, bulk drugs, traditional Chinese medicines, as well as diagnostic reagents and equipment. Its drug address serious conditions such as gastrointestinal, cardiovascular, anti-infectious, antimicrobial, antineoplastic, hemopoietic system, and other conditions. The Company distributes its products within domestic markets and to overseas markets. The company operates in a single reportable segment that is pharmaceutical manufacturing.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
SHE
Primary Office
- No.132, Guihua Road North
- Gongbei, Zhuhai
- Guangdong, 519020
- China
+86 175 0000 0000
Livzon Pharmaceutical Group Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.05 | $5.23 | $4.04 - $6.85 | $4.32B | 936M | 10.9M | $0.30 |
Livzon Pharmaceutical Group Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 2,683,746 | 4,282,796 | 4,224,803 | 3,093,834 |
| Revenue | 1,858,630 | 1,868,316 | 1,522,797 | 1,358,203 |
| EBITDA | 306,062 | 404,636 | 395,663 | 273,962 |
| Net Income | 279,149 | 274,998 | 248,228 | 188,559 |
| Total Assets | 3,307,588 | 3,509,816 | 3,151,672 | 2,569,241 |
| Total Debt | 492,475 | 422,709 | 295,395 | 194,495 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Livzon Pharmaceutical Group Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Livzon Pharmaceutical Group Inc is engaged in China's healthcare sector. As a pharmaceutical manufacturer, the company's
Drug Discovery
Guangdong, China
8,693
As of 2022
00000
o consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat
0000 000000000
Mumbai, India
00000
As of 0000
00000000
000000
rit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidata
000000000000000
Lagos, Nigeria
00
As of 0000
Add Comparison
Livzon Pharmaceutical Group Competitors (17)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cipla | Corporation | Mumbai, India | 00000 | 00000000 | ||
| 000000000000000 00 | Corporation | Lagos, Nigeria | 00 | |||
| 0000000 0000000000 | Corporation | Ahmedabad, India | 00000 | 0000 | 00000000000 | 0000 |
| 000000000000000 | Corporation | Brentford, United Kingdom | 00000 | 000000000 | ||
| 000000 | Formerly PE-Backed | Bengaluru, India | 00000 | 000.00 | 00000000 | 000.00 |
Livzon Pharmaceutical Group Patents
Livzon Pharmaceutical Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3811941-A1 | Pharmaceutical composition containing ilaprazole or salt thereof and preparation method therefor | Pending | 22-Jun-2018 | 00000000000 | |
| US-20210260046-A1 | Pharmaceutical composition containing ilaprazole or salt thereof and preparation method therefor | Pending | 22-Jun-2018 | 00000000000 | |
| EP-3811941-A4 | Pharmaceutical composition containing ilaprazole or salt thereof and preparation method therefor | Pending | 22-Jun-2018 | 00000000000 | 0 |
| EP-3607940-A4 | Aripiprazole sustained-release microsphere and preparation method therefor | Pending | 16-May-2018 | 0000000000 | |
| EP-3607940-A1 | Aripiprazole sustained-release microsphere and preparation method therefor | Pending | 16-May-2018 | A61K9/1647 |
Livzon Pharmaceutical Group Executive Team (4)
Livzon Pharmaceutical Group Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 000 | Self | Chairman & Board Member | 000 0000 |
| 0000000 000 | Livzon Pharmaceutical Group | Vice Chairman | 000 0000 |
| 00000000 00 | Livzon Pharmaceutical Group | Vice Chairman & Vice President | 000 0000 |
| 000 000 | Livzon Pharmaceutical Group | Board Member | 000 0000 |
| 000 00 0000 | Livzon Pharmaceutical Group | Board Member | 000 0000 |
Livzon Pharmaceutical Group Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Livzon Pharmaceutical Group Investments (15)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 00000 | 21-Sep-2022 | 0000 | 0000 | Drug Discovery | |
| 0000 00000000 | 04-Jan-2022 | 00000 0000 | 000.00 | Drug Discovery | |
| 00000 0000000 | 31-Aug-2021 | 00000 0000 | 0000 | Drug Discovery | |
| 0000000 00000 | 01-Mar-2021 | 00000 0000 | 0000 | Drug Discovery | |
| Elicio Therapeutics | 17-Feb-2021 | Later Stage VC | 00000 | Drug Discovery |
Livzon Pharmaceutical Group Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 000000 00000000 | Drug Discovery | Zhuhai, China | 0000 |
Livzon Pharmaceutical Group Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000 000 | 08-Jan-2020 | 0000 00000 | Completed |
|
|
| EPIRUS Biopharmaceuticals | 16-Apr-2014 | Early Stage VC | 0000 | Completed |
|